融信中國(03301.HK)擬發行2億美元優先票據
格隆匯 7 月 30日丨融信中國(03301.HK)發佈公告,2020年7月29日,公司及附屬公司擔保人與瑞士信貸、花旗、國泰君安國際、海通國際、東方證券(香港)及瑞銀就發行於2024年到期的2億美元的6.75%優先票據訂立購買協議。
票據發行的所得款項總額,未扣除有關票據發行的包銷折扣及佣金以及其他開支,為2億美元。公司擬將票據發行的所得款項淨額用於其若干現有債務的再融資。票據已獲新交所原則上批准於新交所上市及報價。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.